Adaptive Biotechnologies (ADPT) 10-Q 4 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	Apr. 29, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Trading Symbol	ADPT
Entity Registrant Name	ADAPTIVE BIOTECHNOLOGIES CORPORATION
Entity Central Index Key	0001478320
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		142,227,952
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity File Number	001-38957
Entity Tax Identification Number	27-0907024
Entity Address, Address Line One	1165 Eastlake Avenue East
Entity Address, City or Town	Seattle
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98109
City Area Code	(206)
Local Phone Number	659-0067
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	WA

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 114,805,000	$ 139,065,000
Short-term marketable securities (amortized cost of $250,448 and $214,115, respectively)	248,757,000	213,996,000
Accounts receivable, net	22,518,000	17,409,000
Inventory	21,002,000	19,263,000
Prepaid expenses and other current assets	12,038,000	13,015,000
Total current assets	419,120,000	402,748,000
Long-term assets
Property and equipment, net	85,994,000	85,262,000
Operating lease right-of-use assets	85,634,000	87,678,000
Long-term marketable securities (amortized cost of $140,202 and $218,163, respectively)	137,110,000	217,145,000
Restricted cash	2,382,000	2,138,000
Intangible assets, net	8,107,000	8,526,000
Goodwill	118,972,000	118,972,000
Other assets	874,000	875,000
Total assets	858,193,000	923,344,000
Current liabilities
Accounts payable	5,959,000	3,307,000
Accrued liabilities	10,407,000	9,343,000
Accrued compensation and benefits	6,651,000	15,642,000
Current portion of operating lease liabilities	8,545,000	5,055,000
Current portion of deferred revenue	83,504,000	80,460,000
Total current liabilities	115,066,000	113,807,000
Long-term liabilities
Operating lease liabilities, less current portion	104,978,000	106,685,000
Deferred revenue, less current portion	84,894,000	98,750,000
Total liabilities	304,938,000	319,242,000
Commitments and contingencies (Note 9)
Shareholders’ equity
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at March 31, 2022 and December 31, 2021; no shares issued and outstanding at March 31, 2022 and December 31, 2021
Common stock: $0.0001 par value, 340,000,000 shares authorized at March 31, 2022 and December 31, 2021; 142,183,258 and 141,393,865 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	14,000	14,000
Additional paid-in capital	1,339,601,000	1,324,006,000
Accumulated other comprehensive loss	(4,783,000)	(1,137,000)
Accumulated deficit	(781,627,000)	(718,891,000)
Total Adaptive Biotechnologies Corporation shareholders’ equity	553,205,000	603,992,000
Noncontrolling interest	50,000	110,000
Total shareholders’ equity	553,255,000	604,102,000
Total liabilities and shareholders’ equity	$ 858,193,000	$ 923,344,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Amortized cost of short-term marketable securities	$ 250,448	$ 214,115
Amortized cost of long-term marketable securities	$ 140,202	$ 218,163
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock authorized	10,000,000	10,000,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Common stock par value	$ 0.0001	$ 0.0001
Common stock authorized	340,000,000	340,000,000
Common stock issued	142,183,258	141,393,865
Common stock outstanding	142,183,258	141,393,865

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue	$ 38,620	$ 38,442
Operating expenses
Cost of revenue	13,192	9,991
Research and development	37,839	33,772
Sales and marketing	26,093	20,604
General and administrative	24,144	14,936
Amortization of intangible assets	419	419
Total operating expenses	101,687	79,722
Loss from operations	(63,067)	(41,280)
Interest and other income, net	271	638
Net loss	(62,796)	(40,642)
Add: Net loss attributable to noncontrolling interest	60
Net loss attributable to Adaptive Biotechnologies Corporation	$ (62,736)	$ (40,642)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$ (0.44)	$ (0.29)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	141,697,252	138,967,754

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement Of Financial Position [Abstract]
Net loss	$ (62,796)	$ (40,642)
Other comprehensive loss
Change in unrealized gains and losses on investments	(3,646)	(262)
Comprehensive loss	(66,442)	(40,904)
Add: Comprehensive loss attributable to noncontrolling interest	60
Comprehensive loss attributable to Adaptive Biotechnologies Corporation	$ (66,382)	$ (40,904)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit	Noncontrolling Interest
Beginning Balance at Dec. 31, 2020	$ 743,266	$ 14	$ 1,253,971	$ 893	$ (511,612)
Beginning Balance, Shares at Dec. 31, 2020		137,646,896
Issuance of common stock upon exercise of common stock warrants, Shares		54,162
Issuance of common stock for cash upon exercise of stock options	14,442		14,442
Issuance of common stock for cash upon exercise of stock options, Shares		2,183,640
Common stock option and restricted stock unit share-based compensation	8,484		8,484
Capital contributions for Digital Biotechnologies, Inc.	429		300			$ 129
Other comprehensive loss	(262)			(262)
Net loss	(40,642)				(40,642)
Ending Balance at Mar. 31, 2021	725,717	$ 14	1,277,197	631	(552,254)	129
Ending Balance, Shares at Mar. 31, 2021		139,884,698
Beginning Balance at Dec. 31, 2021	604,102	$ 14	1,324,006	(1,137)	(718,891)	110
Beginning Balance, Shares at Dec. 31, 2021		141,393,865
Issuance of common stock for cash upon exercise of stock options	$ 2,734		2,734
Issuance of common stock for cash upon exercise of stock options, Shares	648,208	648,208
Vesting of restricted stock units		141,185
Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation	$ 12,861		12,861
Other comprehensive loss	(3,646)			(3,646)
Net loss	(62,796)				(62,736)	(60)
Ending Balance at Mar. 31, 2022	$ 553,255	$ 14	$ 1,339,601	$ (4,783)	$ (781,627)	$ 50
Ending Balance, Shares at Mar. 31, 2022		142,183,258

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net loss	$ (62,796)	$ (40,642)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	4,637	2,252
Noncash lease expense	1,792	1,732
Share-based compensation expense	12,861	8,484
Intangible assets amortization	419	419
Investment amortization	862	2,108
Other	(20)	(9)
Changes in operating assets and liabilities
Accounts receivable, net	(5,109)	(9,707)
Inventory	(1,739)	(3,359)
Prepaid expenses and other current assets	962	1,273
Accounts payable and accrued liabilities	(7,545)	(7,257)
Operating lease right-of-use assets and liabilities	2,035	813
Deferred revenue	(10,812)	(14,233)
Other		(119)
Net cash used in operating activities	(64,453)	(58,245)
Investing activities
Purchases of property and equipment	(3,077)	(15,841)
Purchases of marketable securities	(60,235)	(15,340)
Proceeds from maturities of marketable securities	101,000	125,000
Net cash provided by investing activities	37,688	93,819
Financing activities
Proceeds from exercise of stock options	2,749	14,185
Proceeds from initial capital contributions for Digital Biotechnologies, Inc.		429
Net cash provided by financing activities	2,749	14,614
Net (decrease) increase in cash, cash equivalents and restricted cash	(24,016)	50,188
Cash, cash equivalents and restricted cash at beginning of year	141,203	125,574
Cash, cash equivalents and restricted cash at end of period	117,187	175,762
Noncash investing activities
Purchases of equipment included in accounts payable and accrued liabilities	$ 2,952	$ 7,698

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	1. Organization Adaptive Biotechnologies Corporation (“we,” “us” or “our”) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer, autoimmune disorders and infectious diseases. We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Basis Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, our wholly-owned subsidiary and Digital Biotechnologies, Inc., a corporate subsidiary we have 70% ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the unaudited condensed consolidated financial statements as noncontrolling interest. All intercompany transactions and balances between Adaptive Biotechnologies Corporation, our wholly-owed subsidiary and Digital Biotechnologies, Inc. have been eliminated upon consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates. Unaudited Interim Condensed Consolidated Financial Statements In our opinion, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state our financial position and the results of our operations and cash flows for interim periods in accordance with GAAP. All such adjustments were of a normal, recurring nature. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 15, 2022. Reclassification We previously disclosed revenue bifurcated into sequencing and development financial statement captions and now present total revenue on the unaudited condensed consolidated statements of operations. See Note 3, Revenue for additional disaggregation of revenue under our Immune Medicine and MRD market opportunities. Restricted Cash We had a restricted cash balance of $2.4 million and $2.1 million as of March 31, 2022 and December 31, 2021, respectively. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our property and facility leases. Concentrations We are subject to a concentration of risk from a limited number of suppliers, or in certain cases single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock. Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, United States (“U.S.”) government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions. Significant customers are those that represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each condensed consolidated balance sheet date presented, respectively. For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: Revenue Accounts Receivable, Net Three Months Ended March 31, March 31, December 31, 2022 2021 2022 2021 Customer A *% *% 15.1 % *% Customer B 17.9 10.4 30.1 11.3 Customer C * 10.0 * * Genentech and Roche Group 33.8 42.1 * * * less than 10% Revenue We recognize revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”), Revenue from Contracts with Customers We derive revenue by providing diagnostic and research services in our Immune Medicine and MRD market opportunities. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, immunoSEQ, to biopharmaceutical customers and academic institutions; (2) providing our T-Detect COVID tests to clinical customers; and (3) our collaboration agreements with Genentech and other biopharmaceutical customers in areas of drug and target discovery. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers. For research customers who utilize either immunoSEQ or our MRD services, contracts typically include an amount billed in advance of services (“upfront”) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: (1) the delivery of our immunoSEQ or MRD data for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the remaining samples expected to be delivered. For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from medical institutions and commercial and government third-party payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience. Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report . This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient’s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient’s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing. The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customer’s therapeutic development efforts, including regulatory support for our technology intended to be utilized as part of our customer’s registrational trials, developing analytical plans for our data, participating on joint research committees and assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for their regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers’ own submission decision-making. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Milestone payments for regulatory approvals, which are not within our customers’ control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone. Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders We calculate basic net loss per share attributable to our common shareholders by dividing net loss attributable to us by our weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to our common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, common stock warrants, stock options outstanding, nonvested restricted stock units and the maximum nonvested market-based restricted stock units eligible to be earned are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to our common shareholders, as their effect is anti-dilutive.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Revenue	3. Revenue We disaggregate our revenue from contracts with customers by market opportunity and type of arrangement, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The following table presents our disaggregated revenue for the periods presented (in thousands): Three Months Ended March 31, 2022 2021 Immune Medicine revenue Service revenue $ 7,113 $ 4,048 Collaboration revenue 13,703 16,057 Total Immune Medicine revenue 20,816 20,105 MRD revenue Service revenue 14,804 11,337 Regulatory milestone revenue 3,000 7,000 Total MRD revenue 17,804 18,337 Total revenue $ 38,620 $ 38,442 During the three months ended March 31, 2022, we recognized $1.4 million in revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, cancelled biopharmaceutical customer contracts and changes in estimates of total samples to be provided under certain of our agreements, $0.2 million of which was recognized as Immune Medicine service revenue and $1.2 million of which was recognized as MRD service revenue. During the three months ended March 31, 2021, we recognized $0.8 million in revenue related to changes in estimates of total samples to be provided under certain of our agreements, Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and cancelled biopharmaceutical customer contracts, all of which was recognized as MRD service revenue. As of March 31, 2022, we could receive up to an additional $330.5 million in milestone payments in future periods if certain regulatory approvals are obtained by our customers’ therapeutics in connection with MRD data generated from our MRD product. Genentech In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (the “Genentech Agreement”) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $300.0 million in February 2019 and may be eligible to receive more than $1.8 billion over time, including payments of up to $75.0 million upon the achievement of specified regulatory milestones, up to $300.0 million upon the achievement of specified development milestones and up to $1,430.0 million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the agreement, we are pursuing two product development pathways for novel T cell immunotherapies in which Genentech intends to use T cell receptors (“TCRs”) screened by our immune medicine platform to engineer and manufacture cellular medicines: • Shared Products. The shared products will use “off-the-shelf” TCRs identified against cancer antigens shared among patients (“Shared Products”). • Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (“Personalized Product”). Under the terms of the agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in ASC Topic 808, Collaborative Arrangements In applying ASC 606, we identified the following performance obligations at the inception of the agreement: 1. License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology. 2. License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology. 3. License to utilize all private antigen TCR product data in connection with research and development activities in the field of use. 4. License to existing shared antigen data packages. 5. Research and development services for Shared Products development, including expansion of shared antigen data packages. 6. Research and development services for private product development. 7. Obligations to participate on various joint research, development and project committees. We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech’s control of product commercialization. Specifically, under the agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway. Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties. We determined the initial transaction price shall be made up of only the $300.0 million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the transaction price as of March 31, 2022. We excluded the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur. As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize the revenue over a period of approximately seven to eight years from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Products and the Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known. We recognized $12.3 million and $15.6 million in Immune Medicine collaboration revenue during the three months ended March 31, 2022 and 2021, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.

Deferred Revenue

Deferred Revenue	3 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Deferred Revenue	4 . Deferred Revenue Deferred revenue from our Genentech Agreement represents $56.9 million and $80.9 million of the current and non-current deferred revenue balances, respectively, as of March 31, 2022 and $56.1 million and $94.0 million of the current and non-current deferred revenue balances, respectively, as of December 31, 2021. In general, we expect that the current amounts will be recognized as revenue within 12 months and the non-current amounts will be recognized as revenue over a period of approximately four to five years from March 31, 2022. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on the various research and development activities. Changes in deferred revenue during the three months ended March 31, 2022 were as follows (in thousands): Deferred revenue balance at December 31, 2021 $ 179,210 Additions to deferred revenue during the period 8,907 Revenue recognized during the period (19,719 ) Deferred revenue balance at March 31, 2022 $ 168,398 As of March 31, 2022, $16.0 million was recognized as revenue that was included in the deferred revenue balance at December 31, 2021.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	5 . Fair Value The following tables set forth the fair value of financial assets as of March 31, 2022 and December 31, 2021 that were measured at fair value on a recurring basis (in thousands): March 31, 2022 Level 1 Level 2 Level 3 Total Financial assets Money market funds $ 92,096 $ — $ — $ 92,096 U.S. government debt securities — 358,291 — 358,291 Corporate bonds — 39,573 — 39,573 Total financial assets $ 92,096 $ 397,864 $ — $ 489,960 December 31, 2021 Level 1 Level 2 Level 3 Total Financial assets Money market funds $ 131,946 $ — $ — $ 131,946 U.S. government debt securities — 391,145 — 391,145 Corporate bonds — 39,996 — 39,996 Total financial assets $ 131,946 $ 431,141 $ — $ 563,087 Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government debt securities and corporate bonds, and are valued based on recent trades of securities in inactive markets or on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. Of the March 31, 2022 Level 2 U.S. government debt securities balance, $12.0 million is recorded within the cash and cash equivalents balance on the unaudited condensed consolidated balance sheet as of March 31, 2022.

Investments

Investments	3 Months Ended
	Mar. 31, 2022
Investments Debt And Equity Securities [Abstract]
Investments	6 . Investments Available-for-sale investments consisted of the following as of March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 Amortized Cost Unrealized Gain Unrealized Loss Estimated Fair Value Short-term marketable securities U.S. government debt securities $ 210,589 $ — $ (1,405 ) $ 209,184 Corporate bonds 39,859 — (286 ) 39,573 Total short-term marketable securities $ 250,448 $ — $ (1,691 ) $ 248,757 Long-term marketable securities U.S. government debt securities $ 140,202 $ — $ (3,092 ) $ 137,110 Total long-term marketable securities $ 140,202 $ — $ (3,092 ) $ 137,110 December 31, 2021 Amortized Cost Unrealized Gain Unrealized Loss Estimated Fair Value Short-term marketable securities U.S. government debt securities $ 186,752 $ 4 $ (109 ) $ 186,647 Corporate bonds 27,363 — (14 ) 27,349 Total short-term marketable securities $ 214,115 $ 4 $ (123 ) $ 213,996 Long-term marketable securities U.S. government debt securities $ 205,472 $ — $ (974 ) $ 204,498 Corporate bonds 12,691 — (44 ) 12,647 Total long-term marketable securities $ 218,163 $ — $ (1,018 ) $ 217,145 All the U.S. government debt securities and corporate bonds designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective condensed consolidated balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective condensed consolidated balance sheet date. Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivable of $1.1 million and $1.4 million is presented separately within the prepaid expenses and other current assets balance on the unaudited condensed consolidated balance sheet as of March 31, 2022 and on the condensed consolidated balance sheet as of December 31, 2021, respectively. The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of March 31, 2022 (in thousands): Less Than 12 Months 12 Months Or Greater Fair Value Unrealized Loss Fair Value Unrealized Loss U.S. government debt securities $ 346,294 $ (4,497 ) $ — $ — Corporate bonds 39,573 (286 ) — — Total available-for-sale securities $ 385,867 $ (4,783 ) $ — $ — We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data. As of March 31, 2022, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of March 31, 2022 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	7 . Goodwill There have been no changes in the carrying amount of goodwill since its recognition in 2015. Intangible assets subject to amortization as of March 31, 2022 and December 31, 2021 consisted of the following (in thousands): March 31, 2022 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Acquired developed technology $ 20,000 $ (12,049 ) $ 7,951 Purchased intellectual property 325 (169 ) 156 Balance at March 31, 2022 $ 20,325 $ (12,218 ) $ 8,107 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Acquired developed technology $ 20,000 $ (11,638 ) $ 8,362 Purchased intellectual property 325 (161 ) 164 Balance at December 31, 2021 $ 20,325 $ (11,799 ) $ 8,526 The developed technology was acquired in connection with our acquisition of Sequenta, Inc. in 2015. The remaining balance of the acquired technology and the purchased intellectual property is expected to be amortized over the next 4.8 years. As of March 31, 2022, expected future amortization expense for intangible assets was as follows (in thousands): 2022 (excluding the three months ended March 31, 2022) $ 1,280 2023 1,699 2024 1,703 2025 1,699 2026 1,699 Thereafter 27 Total future amortization expense $ 8,107

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Lessee Disclosure [Abstract]
Leases	8. Leases We have operating lease agreements for laboratory, office and warehouse facilities in Seattle, Washington, Bothell, Washington, South San Francisco, California and New York City, New York. As of , we were not party to any finance leases. The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance as of (in thousands): 2022 (excluding the three months ended March 31, 2022) $ 10,618 2023 13,964 2024 13,692 2025 14,098 2026 12,330 Thereafter 81,188 Total undiscounted lease payments 145,890 Less: Imputed interest rate (31,087 ) Tenant improvement receivables (1,280 ) Total operating lease liabilities 113,523 Less: Current portion (8,545 ) Operating lease liabilities, less current portion $ 104,978 Cash paid for amounts included in the measurement of lease liabilities was $3.3 million and cash received for tenant improvement allowances was $4.0 million during the three months ended March 31, 2022. During the three months ended March 31, 2021, cash paid for amounts included in the measurement of lease liabilities was $0.5 million, net of $1.2 million of cash received for tenant improvement allowances. We previously entered into a $2.1 million letter of credit with one of our financial institutions in connection with one of our leases.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	9 . Commitments and Contingencies Legal Proceedings We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We were not party to any material legal proceedings as of March 31, 2022. Indemnification Agreements In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Shareholders' Equity	10 . Shareholders’ Common Stock Our common stock has no preferences or privileges and is not redeemable. Holders of our common stock are entitled to one vote for each share of common stock held. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time. As of March 31, 2022, we had reserved shares of common stock for the following: Shares issuable upon the exercise of outstanding stock options granted 15,015,928 Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned 5,984,738 Shares available for future grant under the 2019 Equity Incentive Plan 14,500,039 Shares available for future grant under the Employee Stock Purchase Plan 2,804,298 Total shares of common stock reserved for future issuance 38,305,003 Our 2019 Equity Incentive Plan (“2019 Plan”) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors. Furthermore, our Employee Stock Purchase Plan (“ESPP”) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) 1% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors. Our board of directors determined not to increase the 2019 Plan and ESPP reserves in 2022.

Equity Incentive Plans

Equity Incentive Plans	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plans	1 1 . Equity Incentive Plans 2009 Equity Incentive Plan We adopted an equity incentive plan in 2009 (“2009 Plan”) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Stock options granted under this plan expire no later than ten years from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding stock options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While no shares are available for future issuance under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder. 2019 Equity Incentive Plan The 2019 Plan became effective immediately prior to the closing of our initial public offering in July 2019. The 2019 Plan provides for the issuance of awards in the form of stock options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the stock option exercise price per share shall not be less than the fair market value of a share of stock on the effective date of grant, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, stock options granted under this plan expire no later than ten years from the grant date and vesting is established at the time of grant. Except for certain stock option and restricted stock unit grants made to non-employee directors, stock options and restricted stock units granted under the 2019 Plan generally vest over a four-year Changes in shares available for grant during the three months ended March 31, 2022 were as follows: Shares Available for Grant Shares available for grant at December 31, 2021 22,299,923 Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned (9,178,494 ) Stock options and restricted stock units forfeited, cancelled or expired 1,378,610 Shares available for grant at March 31, 2022 14,500,039 Stock Options Stock option activity under the 2009 Plan and 2019 Plan during the three months ended March 31, 2022 was as follows: Shares Subject to Outstanding Stock Options Weighted-Average Exercise Price per Share Aggregate Intrinsic Value (in thousands) Stock options outstanding at December 31, 2021 12,778,984 $ 19.72 Stock options granted 3,730,851 12.43 Stock options forfeited or cancelled (795,626 ) 29.00 Stock options expired (50,073 ) 34.73 Stock options exercised (648,208 ) 4.22 Stock options outstanding at March 31, 2022 15,015,928 $ 18.03 $ 51,641 Stock options vested and exercisable at March 31, 2022 7,387,511 $ 13.42 $ 42,129 The weighted-average remaining contractual life for stock options outstanding as of March 31, 2022 was 7.3 years. The weighted-average remaining contractual life for vested and exercisable stock options as of March 31, 2022 was 5.4 years. Of the $14.2 million of proceeds from the exercise of stock options included on the unaudited condensed consolidated statements of cash flows for the three months ended March 31, 2021, $0.3 million related to stock options exercised prior to but settled during the three months ended March 31, 2021. Furthermore, $0.5 million of proceeds from stock options exercised during the three months ended March 31, 2021 were unsettled as of March 31, 2021. Restricted Stock Units Restricted stock unit activity under the 2019 Plan during the three months ended March 31, 2022 was as follows: Restricted Stock Units Outstanding Weighted-Average Grant Date Fair Value per Share Nonvested restricted stock units outstanding at December 31, 2021 1,211,191 $ 37.41 Restricted stock units granted 4,953,409 12.17 Restricted stock units forfeited or cancelled (532,911 ) 17.37 Restricted stock units vested (141,185 ) 44.57 Nonvested restricted stock units outstanding at March 31, 2022 5,490,504 $ 16.40 Market-Based Restricted Stock Units In addition to the restricted stock units described above, our board of directors approved an award of market-based restricted stock units to our chief executive officer in March 2022. The shares of common stock that may be earned under the award, ranging from zero shares to 494,234 shares, are calculated based upon our total shareholder return during a three-year Grant Date Fair Value of Stock Options, Restricted Stock Units and Market-Based Restricted Stock Units Granted The estimated grant date fair values of stock options granted during the three months ended March 31, 2022 and 2021 were estimated using the Black-Scholes option-pricing model with the following assumptions: Three Months Ended March 31, 2022 2021 Fair value of common stock $12.14 - $14.95 $43.68 - $66.50 Expected term (in years) 5.27 - 6.08 5.27 - 6.08 Risk-free interest rate 1.7% - 2.5% 0.5% - 1.1% Expected volatility 68.2% - 69.8% 67.1% - 68.4% Expected dividend yield — — The determination of the grant date fair value of stock options granted using a Black-Scholes option-pricing model is affected by the fair value of our common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows: Fair value of common stock— The fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market. Expected term —The expected term of stock options granted to employees and non-employee directors is determined using the “simplified” method, as illustrated in ASC Topic 718, , as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is based on the midpoint between the vesting date and the end of the contractual term of the stock option. Risk-free interest rate —We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the stock options. Expected volatility —As we do not have sufficient trading history for our common stock, the expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term. Expected dividend yield —We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of zero in the option valuation model. The weighted-average grant date fair value per share of stock options granted during the three months ended March 31, 2022 and 2021 was $7.81 and $27.67, respectively. The grant date fair value of restricted stock units granted is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market. The weighted-average grant date fair value per share of restricted stock units granted during the three months ended March 31, 2022 and 2021 was $12.17 and $44.10, respectively. The grant date fair value of the market-based restricted stock units granted in March 2022 is $18.89 and was determined using a Monte Carlo valuation model, which uses assumptions such as volatility, risk-free interest rate and dividend estimated for the performance period. The related share-based compensation expense of $4.7 million is recognized on a straight-line basis over the three-year The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the three months ended March 31, 2022 and 2021 are included on the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months Ended March 31, 2022 2021 Cost of revenue $ 795 $ 328 Research and development 4,345 2,883 Sales and marketing 3,229 2,495 General and administrative 4,492 2,778 Total share-based compensation expense $ 12,861 $ 8,484 As of March 31, 2022, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows: Unrecognized Share-Based Compensation Expense (in thousands) Remaining Weighted-Average Recognition Period (in years) Nonvested stock options $ 102,285 3.02 Nonvested restricted stock units 85,458 3.63 Nonvested market-based restricted stock units 4,553 2.93

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2022
Restructuring And Related Activities [Abstract]
Restructuring	12. Restructuring In March 2022, we began implementing a restructuring plan to reduce operating costs and drive future growth aligned with the strategic reorganization of our business around our MRD and Immune Medicine market opportunities. Under this restructuring plan, we reduced our workforce by approximately 100 employees. We estimate that we will incur aggregate restructuring costs of approximately $2.0 million, all of which has been recognized in the three months ended March 31, 2022. These costs primarily relate to one-time termination benefits and ongoing benefit arrangements, both of which include severance payments and extended benefits coverage support and are contingent upon the impacted employees’ execution and non-revocation of separation agreements. Our estimated aggregate restructuring costs also include certain contract termination costs. The activities related to our reduction in workforce were primarily completed in March 2022 and $1.4 million of the $2.0 million aggregate restructuring costs were paid as of March 31, 2022. The remaining $0.6 million in cash payments are expected to be disbursed in the year ended December 31, 2022.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders	1 3 . Net Loss Shareholders The following table sets forth the computation of the basic and diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2022 and 2021 (in thousands, except share and per share amounts): Three Months Ended March 31, 2022 2021 Net loss attributable to Adaptive Biotechnologies Corporation $ (62,736 ) $ (40,642 ) Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted 141,697,252 138,967,754 Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted $ (0.44 ) $ (0.29 ) Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2022 and 2021 as they had an anti-dilutive effect: Three Months Ended March 31, 2022 2021 Stock options outstanding 13,255,459 13,516,949 Nonvested restricted stock units 2,587,492 238,583 Maximum nonvested market-based restricted stock units eligible to be earned 153,762 — Common stock warrant — 34,757 Total 15,996,713 13,790,289

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, our wholly-owned subsidiary and Digital Biotechnologies, Inc., a corporate subsidiary we have 70% ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the unaudited condensed consolidated financial statements as noncontrolling interest. All intercompany transactions and balances between Adaptive Biotechnologies Corporation, our wholly-owed subsidiary and Digital Biotechnologies, Inc. have been eliminated upon consolidation.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.
Unaudited Interim Condensed Consolidated Financial Statements	Unaudited Interim Condensed Consolidated Financial Statements In our opinion, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state our financial position and the results of our operations and cash flows for interim periods in accordance with GAAP. All such adjustments were of a normal, recurring nature. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 15, 2022.
Reclassification	Reclassification We previously disclosed revenue bifurcated into sequencing and development financial statement captions and now present total revenue on the unaudited condensed consolidated statements of operations. See Note 3, Revenue for additional disaggregation of revenue under our Immune Medicine and MRD market opportunities.
Restricted Cash	Restricted Cash We had a restricted cash balance of $2.4 million and $2.1 million as of March 31, 2022 and December 31, 2021, respectively. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our property and facility leases.
Concentrations of Risk	Concentrations We are subject to a concentration of risk from a limited number of suppliers, or in certain cases single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock. Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, United States (“U.S.”) government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions. Significant customers are those that represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each condensed consolidated balance sheet date presented, respectively. For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: Revenue Accounts Receivable, Net Three Months Ended March 31, March 31, December 31, 2022 2021 2022 2021 Customer A *% *% 15.1 % *% Customer B 17.9 10.4 30.1 11.3 Customer C * 10.0 * * Genentech and Roche Group 33.8 42.1 * * * less than 10%
Revenue Recognition	Revenue We recognize revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”), Revenue from Contracts with Customers We derive revenue by providing diagnostic and research services in our Immune Medicine and MRD market opportunities. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, immunoSEQ, to biopharmaceutical customers and academic institutions; (2) providing our T-Detect COVID tests to clinical customers; and (3) our collaboration agreements with Genentech and other biopharmaceutical customers in areas of drug and target discovery. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers. For research customers who utilize either immunoSEQ or our MRD services, contracts typically include an amount billed in advance of services (“upfront”) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: (1) the delivery of our immunoSEQ or MRD data for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the remaining samples expected to be delivered. For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from medical institutions and commercial and government third-party payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience. Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report . This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient’s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient’s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing. The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customer’s therapeutic development efforts, including regulatory support for our technology intended to be utilized as part of our customer’s registrational trials, developing analytical plans for our data, participating on joint research committees and assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for their regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers’ own submission decision-making. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Milestone payments for regulatory approvals, which are not within our customers’ control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders	Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders We calculate basic net loss per share attributable to our common shareholders by dividing net loss attributable to us by our weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to our common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, common stock warrants, stock options outstanding, nonvested restricted stock units and the maximum nonvested market-based restricted stock units eligible to be earned are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to our common shareholders, as their effect is anti-dilutive.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Concentrations of Risk Percentage	For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: Revenue Accounts Receivable, Net Three Months Ended March 31, March 31, December 31, 2022 2021 2022 2021 Customer A *% *% 15.1 % *% Customer B 17.9 10.4 30.1 11.3 Customer C * 10.0 * * Genentech and Roche Group 33.8 42.1 * * * less than 10%

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Schedule of Disaggregated Revenue	The following table presents our disaggregated revenue for the periods presented (in thousands): Three Months Ended March 31, 2022 2021 Immune Medicine revenue Service revenue $ 7,113 $ 4,048 Collaboration revenue 13,703 16,057 Total Immune Medicine revenue 20,816 20,105 MRD revenue Service revenue 14,804 11,337 Regulatory milestone revenue 3,000 7,000 Total MRD revenue 17,804 18,337 Total revenue $ 38,620 $ 38,442

Deferred Revenue (Tables)

Deferred Revenue (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Schedule of Changes in Deferred Revenue	Changes in deferred revenue during the three months ended March 31, 2022 were as follows (in thousands): Deferred revenue balance at December 31, 2021 $ 179,210 Additions to deferred revenue during the period 8,907 Revenue recognized during the period (19,719 ) Deferred revenue balance at March 31, 2022 $ 168,398

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables set forth the fair value of financial assets as of March 31, 2022 and December 31, 2021 that were measured at fair value on a recurring basis (in thousands): March 31, 2022 Level 1 Level 2 Level 3 Total Financial assets Money market funds $ 92,096 $ — $ — $ 92,096 U.S. government debt securities — 358,291 — 358,291 Corporate bonds — 39,573 — 39,573 Total financial assets $ 92,096 $ 397,864 $ — $ 489,960 December 31, 2021 Level 1 Level 2 Level 3 Total Financial assets Money market funds $ 131,946 $ — $ — $ 131,946 U.S. government debt securities — 391,145 — 391,145 Corporate bonds — 39,996 — 39,996 Total financial assets $ 131,946 $ 431,141 $ — $ 563,087

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2022
Investments Debt And Equity Securities [Abstract]
Schedule of Available-for-sale Investments	Available-for-sale investments consisted of the following as of March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 Amortized Cost Unrealized Gain Unrealized Loss Estimated Fair Value Short-term marketable securities U.S. government debt securities $ 210,589 $ — $ (1,405 ) $ 209,184 Corporate bonds 39,859 — (286 ) 39,573 Total short-term marketable securities $ 250,448 $ — $ (1,691 ) $ 248,757 Long-term marketable securities U.S. government debt securities $ 140,202 $ — $ (3,092 ) $ 137,110 Total long-term marketable securities $ 140,202 $ — $ (3,092 ) $ 137,110 December 31, 2021 Amortized Cost Unrealized Gain Unrealized Loss Estimated Fair Value Short-term marketable securities U.S. government debt securities $ 186,752 $ 4 $ (109 ) $ 186,647 Corporate bonds 27,363 — (14 ) 27,349 Total short-term marketable securities $ 214,115 $ 4 $ (123 ) $ 213,996 Long-term marketable securities U.S. government debt securities $ 205,472 $ — $ (974 ) $ 204,498 Corporate bonds 12,691 — (44 ) 12,647 Total long-term marketable securities $ 218,163 $ — $ (1,018 ) $ 217,145
Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position	The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of March 31, 2022 (in thousands): Less Than 12 Months 12 Months Or Greater Fair Value Unrealized Loss Fair Value Unrealized Loss U.S. government debt securities $ 346,294 $ (4,497 ) $ — $ — Corporate bonds 39,573 (286 ) — — Total available-for-sale securities $ 385,867 $ (4,783 ) $ — $ —

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets Subject to Amortization	Intangible assets subject to amortization as of March 31, 2022 and December 31, 2021 consisted of the following (in thousands): March 31, 2022 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Acquired developed technology $ 20,000 $ (12,049 ) $ 7,951 Purchased intellectual property 325 (169 ) 156 Balance at March 31, 2022 $ 20,325 $ (12,218 ) $ 8,107 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Acquired developed technology $ 20,000 $ (11,638 ) $ 8,362 Purchased intellectual property 325 (161 ) 164 Balance at December 31, 2021 $ 20,325 $ (11,799 ) $ 8,526
Schedule of Future Amortization Expense for Intangible Assets	As of March 31, 2022, expected future amortization expense for intangible assets was as follows (in thousands): 2022 (excluding the three months ended March 31, 2022) $ 1,280 2023 1,699 2024 1,703 2025 1,699 2026 1,699 Thereafter 27 Total future amortization expense $ 8,107

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Lessee Disclosure [Abstract]
Summary of Reconciles Undiscounted Operating Lease Cash Flows	The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance as of (in thousands): 2022 (excluding the three months ended March 31, 2022) $ 10,618 2023 13,964 2024 13,692 2025 14,098 2026 12,330 Thereafter 81,188 Total undiscounted lease payments 145,890 Less: Imputed interest rate (31,087 ) Tenant improvement receivables (1,280 ) Total operating lease liabilities 113,523 Less: Current portion (8,545 ) Operating lease liabilities, less current portion $ 104,978

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Summary of Reserved Shares of Common Stock	As of March 31, 2022, we had reserved shares of common stock for the following: Shares issuable upon the exercise of outstanding stock options granted 15,015,928 Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned 5,984,738 Shares available for future grant under the 2019 Equity Incentive Plan 14,500,039 Shares available for future grant under the Employee Stock Purchase Plan 2,804,298 Total shares of common stock reserved for future issuance 38,305,003

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Changes in Shares Available for Grant	Changes in shares available for grant during the three months ended March 31, 2022 were as follows: Shares Available for Grant Shares available for grant at December 31, 2021 22,299,923 Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned (9,178,494 ) Stock options and restricted stock units forfeited, cancelled or expired 1,378,610 Shares available for grant at March 31, 2022 14,500,039
Summary of Stock Option Activity Under 2009 Plan and 2019 Plan	Stock option activity under the 2009 Plan and 2019 Plan during the three months ended March 31, 2022 was as follows: Shares Subject to Outstanding Stock Options Weighted-Average Exercise Price per Share Aggregate Intrinsic Value (in thousands) Stock options outstanding at December 31, 2021 12,778,984 $ 19.72 Stock options granted 3,730,851 12.43 Stock options forfeited or cancelled (795,626 ) 29.00 Stock options expired (50,073 ) 34.73 Stock options exercised (648,208 ) 4.22 Stock options outstanding at March 31, 2022 15,015,928 $ 18.03 $ 51,641 Stock options vested and exercisable at March 31, 2022 7,387,511 $ 13.42 $ 42,129
Summary of Restricted Stock Unit Activity	Restricted stock unit activity under the 2019 Plan during the three months ended March 31, 2022 was as follows: Restricted Stock Units Outstanding Weighted-Average Grant Date Fair Value per Share Nonvested restricted stock units outstanding at December 31, 2021 1,211,191 $ 37.41 Restricted stock units granted 4,953,409 12.17 Restricted stock units forfeited or cancelled (532,911 ) 17.37 Restricted stock units vested (141,185 ) 44.57 Nonvested restricted stock units outstanding at March 31, 2022 5,490,504 $ 16.40
Summary of Estimated Grant Date Fair Value of Stock Options Granted	The estimated grant date fair values of stock options granted during the three months ended March 31, 2022 and 2021 were estimated using the Black-Scholes option-pricing model with the following assumptions: Three Months Ended March 31, 2022 2021 Fair value of common stock $12.14 - $14.95 $43.68 - $66.50 Expected term (in years) 5.27 - 6.08 5.27 - 6.08 Risk-free interest rate 1.7% - 2.5% 0.5% - 1.1% Expected volatility 68.2% - 69.8% 67.1% - 68.4% Expected dividend yield — —
Summary of Compensation Costs Related to Stock Options and RSUs Included on Unaudited Condensed Consolidated Statements of Operations	The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the three months ended March 31, 2022 and 2021 are included on the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months Ended March 31, 2022 2021 Cost of revenue $ 795 $ 328 Research and development 4,345 2,883 Sales and marketing 3,229 2,495 General and administrative 4,492 2,778 Total share-based compensation expense $ 12,861 $ 8,484
Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period	As of March 31, 2022, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows: Unrecognized Share-Based Compensation Expense (in thousands) Remaining Weighted-Average Recognition Period (in years) Nonvested stock options $ 102,285 3.02 Nonvested restricted stock units 85,458 3.63 Nonvested market-based restricted stock units 4,553 2.93

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders	The following table sets forth the computation of the basic and diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2022 and 2021 (in thousands, except share and per share amounts): Three Months Ended March 31, 2022 2021 Net loss attributable to Adaptive Biotechnologies Corporation $ (62,736 ) $ (40,642 ) Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted 141,697,252 138,967,754 Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted $ (0.44 ) $ (0.29 )
Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share	The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2022 and 2021 as they had an anti-dilutive effect: Three Months Ended March 31, 2022 2021 Stock options outstanding 13,255,459 13,516,949 Nonvested restricted stock units 2,587,492 238,583 Maximum nonvested market-based restricted stock units eligible to be earned 153,762 — Common stock warrant — 34,757 Total 15,996,713 13,790,289

Significant Accounting Polici_4

Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Significant Accounting Policies [Line Items]
Restricted cash	$ 2,382	$ 2,138
Digital Biotechnologies Inc
Significant Accounting Policies [Line Items]
Ownership interest percentage	70.00%

Significant Accounting Polici_5

Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details) - Customer Concentration Risk	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Customer A | Accounts Receivable, Net
Significant Accounting Policies [Line Items]
Concentration risk, percentage	15.10%
Customer B | Revenue
Significant Accounting Policies [Line Items]
Concentration risk, percentage	17.90%	10.40%
Customer B | Accounts Receivable, Net
Significant Accounting Policies [Line Items]
Concentration risk, percentage	30.10%		11.30%
Customer C | Revenue
Significant Accounting Policies [Line Items]
Concentration risk, percentage		10.00%
Genentech Inc And Roche Group | Revenue
Significant Accounting Policies [Line Items]
Concentration risk, percentage	33.80%	42.10%

Revenue - Schedule of Disaggreg

Revenue - Schedule of Disaggregated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation Of Revenue [Line Items]
Revenue	$ 38,620	$ 38,442
Immune Medicine Revenue
Disaggregation Of Revenue [Line Items]
Revenue	20,816	20,105
Immune Medicine Revenue | Service Revenue
Disaggregation Of Revenue [Line Items]
Revenue	7,113	4,048
Immune Medicine Revenue | Collaboration Revenue
Disaggregation Of Revenue [Line Items]
Revenue	13,703	16,057
MRD Revenue
Disaggregation Of Revenue [Line Items]
Revenue	17,804	18,337
MRD Revenue | Service Revenue
Disaggregation Of Revenue [Line Items]
Revenue	14,804	11,337
MRD Revenue | Regulatory Milestone Revenue
Disaggregation Of Revenue [Line Items]
Revenue	$ 3,000	$ 7,000

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 28, 2019	Mar. 31, 2022	Mar. 31, 2021
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement		$ 38,620,000	$ 38,442,000
Medicare Reimbursements
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement		1,400,000	800,000
Medicare Reimbursements | Immune Medicine Service Revenue
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement		200,000
Medicare Reimbursements | MRD Service Revenue
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement		1,200,000
M R D Development Agreements | Maximum
Disaggregation Of Revenue [Line Items]
Additional milestone payment receivable		330,500,000
Genentech Collaboration Agreement
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement		12,300,000	$ 15,600,000
Non-refundable upfront payments received	$ 300,000,000	$ 300,000,000
Genentech Collaboration Agreement | Maximum
Disaggregation Of Revenue [Line Items]
Revenue recognition expected period		8 years
Genentech Collaboration Agreement | Maximum | Regulatory Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments		$ 75,000,000
Genentech Collaboration Agreement | Maximum | Development Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments		300,000,000
Genentech Collaboration Agreement | Maximum | Commercial Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments		1,430,000,000
Genentech Collaboration Agreement | Minimum
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments		$ 1,800,000
Revenue recognition expected period		7 years

Deferred Revenue - Additional I

Deferred Revenue - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Disaggregation Of Revenue [Line Items]
Current deferred revenue	$ 83,504		$ 80,460
Non-current deferred revenue	84,894		98,750
Revenue recognized	(19,719)	$ 16,000
Development Revenue | Genentech, Inc.
Disaggregation Of Revenue [Line Items]
Current deferred revenue	56,900		56,100
Non-current deferred revenue	$ 80,900		$ 94,000

Deferred Revenue - Additional_2

Deferred Revenue - Additional Information (Details1) - Genentech, Inc. - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-04-01	Mar. 31, 2022
Disaggregation Of Revenue [Line Items]
Deferred revenue, expected to be recognized	12 months
Minimum
Disaggregation Of Revenue [Line Items]
Deferred revenue, expected to be recognized	4 years
Maximum
Disaggregation Of Revenue [Line Items]
Deferred revenue, expected to be recognized	5 years

Deferred Revenue - Schedule of

Deferred Revenue - Schedule of Changes in Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Deferred revenue balance at December 31, 2021	$ 179,210
Additions to deferred revenue during the period	8,907
Revenue recognized during the period	(19,719)	$ 16,000
Deferred revenue balance at March 31, 2022	$ 168,398

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Financial assets
Total financial assets	$ 489,960	$ 563,087
Level 1
Financial assets
Total financial assets	92,096	131,946
Level 2
Financial assets
Total financial assets	397,864	431,141
Money Market Funds
Financial assets
Total financial assets	92,096	131,946
Money Market Funds | Level 1
Financial assets
Total financial assets	92,096	131,946
U.S. Government Debt Securities
Financial assets
Total financial assets	358,291	391,145
U.S. Government Debt Securities | Level 2
Financial assets
Total financial assets	358,291	391,145
Corporate Bonds
Financial assets
Total financial assets	39,573	39,996
Corporate Bonds | Level 2
Financial assets
Total financial assets	$ 39,573	$ 39,996

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) $ in Millions	Mar. 31, 2022USD ($)
U.S. Government Debt Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 12

Investments - Schedule of Avail

Investments - Schedule of Available-for-sale Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Short-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	$ 250,448	$ 214,115
Unrealized Gain		4
Unrealized Loss	(1,691)	(123)
Estimated Fair Value	248,757	213,996
Long-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	140,202	218,163
Unrealized Loss	(3,092)	(1,018)
Estimated Fair Value	137,110	217,145
U.S. Government Debt Securities | Short-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	210,589	186,752
Unrealized Gain		4
Unrealized Loss	(1,405)	(109)
Estimated Fair Value	209,184	186,647
U.S. Government Debt Securities | Long-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	140,202	205,472
Unrealized Loss	(3,092)	(974)
Estimated Fair Value	137,110	204,498
Corporate Bonds | Short-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	39,859	27,363
Unrealized Loss	(286)	(14)
Estimated Fair Value	$ 39,573	27,349
Corporate Bonds | Long-Term Marketable Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost		12,691
Unrealized Loss		(44)
Estimated Fair Value		$ 12,647

Investments - Additional Inform

Investments - Additional Information (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Prepaid Expenses and Other Current Assets
Schedule of Available-for-Sale Securities [Line Items]
Accrued interest receivable	$ 1.1	$ 1.4

Investments - Schedule of Gross

Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details) $ in Thousands	Mar. 31, 2022USD ($)
Schedule of Available-for-Sale Securities [Line Items]
Less than 12 months, Fair value	$ 385,867
Less than 12 months, Unrealized loss	(4,783)
U.S. Government Debt Securities
Schedule of Available-for-Sale Securities [Line Items]
Less than 12 months, Fair value	346,294
Less than 12 months, Unrealized loss	(4,497)
Corporate Bonds
Schedule of Available-for-Sale Securities [Line Items]
Less than 12 months, Fair value	39,573
Less than 12 months, Unrealized loss	$ (286)

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2015
Goodwill [Line Items]
Goodwill	$ 118,972,000	$ 118,972,000	$ 0
Purchased Intellectual Property
Goodwill [Line Items]
Amortization period of intangible assets	4 years 9 months 18 days

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 20,325	$ 20,325
Accumulated Amortization	(12,218)	(11,799)
Net Carrying Amount	8,107	8,526
Acquired Developed Technology
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	20,000	20,000
Accumulated Amortization	(12,049)	(11,638)
Net Carrying Amount	7,951	8,362
Purchased Intellectual Property
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	325	325
Accumulated Amortization	(169)	(161)
Net Carrying Amount	$ 156	$ 164

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
2022 (excluding the three months ended March 31, 2022)	$ 1,280
2023	1,699
2024	1,703
2025	1,699
2026	1,699
Thereafter	27
Net Carrying Amount	$ 8,107	$ 8,526

Leases - Summary of Reconciles

Leases - Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Lessee Disclosure [Abstract]
2022 (excluding the three months ended March 31, 2022)	$ 10,618
2023	13,964
2024	13,692
2025	14,098
2026	12,330
Thereafter	81,188
Total undiscounted lease payments	145,890
Imputed interest rate	(31,087)
Tenant improvement receivables	(1,280)
Total operating lease liabilities	113,523
Less: Current portion	(8,545)	$ (5,055)
Operating lease liabilities, less current portion	$ 104,978	$ 106,685

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lessee Disclosure [Abstract]
Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received	$ 3.3	$ 0.5
Cash received for tenant improvement allowances	4	$ 1.2
Letter of credit	$ 2.1

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details) - Vote	Jan. 01, 2020	Mar. 31, 2022
Class Of Stock [Line Items]
Common stock voting rights description		Holders of our common stock are entitled to one vote for each share of common stock held
Number of vote for each share		1
Maximum | Employee Stock Purchase Plan
Class Of Stock [Line Items]
Percentage of annual increases in number of shares	1.00%
2019 Equity Incentive Plan | Maximum
Class Of Stock [Line Items]
Percentage of annual increases in number of shares	5.00%

Shareholders' Equity - Summary

Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)	Mar. 31, 2022shares
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	38,305,003
Shares Issuable Upon the Exercise of Outstanding Stock Options Granted
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	15,015,928
Shares Issuable Upon the Vesting of Outstanding Restricted Stock Units and the Maximum Outstanding Market-based Restricted Stock Units Granted
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	5,984,738
Common Stock Options Granted | 2019 Equity Incentive Plan
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	14,500,039
Common Stock Options Granted | Employee Stock Purchase Plan
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	2,804,298

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average remaining contractual life stock options outstanding	7 years 3 months 18 days
Weighted-average remaining contractual life vested and exercisable stock options	5 years 4 months 24 days
Proceeds from exercise of stock options	$ 2,749	$ 14,185
Proceeds from settlement of stock option exercised in prior periods		300
Unsettled cash proceeds related to stock options exercised		$ 500
Grant date fair value	$ 7.81	$ 27.67
Recognized share-based compensation expense	$ 12,861	$ 8,484
Option Valuation Model
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%
Monte Carlo Valuation Model
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense	$ 4,700
Requisite service period term	3 years
Market-Based Restricted Stock Units | Monte Carlo Valuation Model
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant date fair value	$ 18.89
Market-Based Restricted Stock Units | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance period term	3 years
Market-Based Restricted Stock Units | Minimum | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock that may be earned under the award	0
Market-Based Restricted Stock Units | Maximum | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock that may be earned under the award	494,234
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant date fair value	$ 12.17	$ 44.10
2009 Equity Incentive Plan | Grant
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future issuance	0
2009 Equity Incentive Plan | Grant | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option expiration period	10 years
2019 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future issuance	14,500,039		22,299,923
2019 Equity Incentive Plan | Grant
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized for issuance	29,213,355
2019 Equity Incentive Plan | Grant | Non Employee Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
2019 Equity Incentive Plan | Grant | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option expiration period	10 years
2019 Equity Incentive Plan | Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant date fair value	$ 12.17

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details) - 2019 Equity Incentive Plan	3 Months Ended
	Mar. 31, 2022shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Available for Grant, Outstanding, Beginning Balance	22,299,923
Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned	(9,178,494)
Shares Available for Grant,Stock Options and restricted stock units forfeited, cancelled or expired	1,378,610
Shares Available for Grant, Outstanding, Ending Balance	14,500,039

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding Stock Options, Stock Options outstanding, Beginning Balance | shares	12,778,984
Shares Subject to Outstanding Stock Options, Stock Options granted | shares	3,730,851
Shares Subject to Outstanding Stock Options, Stock Options forfeited or cancelled | shares	(795,626)
Shares Subject to Outstanding Stock Options, Stock Options expired | shares	(50,073)
Shares Subject to Outstanding Stock Options, Stock Options exercised | shares	(648,208)
Shares Subject to Outstanding Stock Options, Stock Options outstanding, Ending Balance | shares	15,015,928
Shares Subject to Outstanding Stock Options, Stock Options vested and exercisable | shares	7,387,511
Weighted Average Exercise Price per Share, Stock Options outstanding, Beginning Balance | $ / shares	$ 19.72
Weighted Average Exercise Price per Share, Stock Options granted | $ / shares	12.43
Weighted Average Exercise Price per Share, Stock Options forfeited or cancelled | $ / shares	29
Weighted Average Exercise Price per Share, Stock Options expired | $ / shares	34.73
Weighted Average Exercise Price per Share, Stock Options exercised | $ / shares	4.22
Weighted Average Exercise Price per Share, Stock Options outstanding, Ending Balance | $ / shares	18.03
Weighted Average Exercise Price per Share, Stock Options vested and exercisable | $ / shares	$ 13.42
Aggregate Intrinsic Value, Stock Option outstanding | $	$ 51,641
Aggregate Intrinsic Value, Stock Options vested and exercisable | $	$ 42,129

Equity Incentive Plans - Summ_3

Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Weighted-Average Grant Date Fair Value per Share
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted	$ 7.81	$ 27.67
Restricted Stock Units (RSUs)
Weighted-Average Grant Date Fair Value per Share
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted	$ 12.17	$ 44.10
Restricted Stock Units (RSUs) | 2019 Equity Incentive Plan
Restricted Stock Units Outstanding
Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance	1,211,191
Restricted Stock Units Outstanding, Granted	4,953,409
Restricted Stock Units Outstanding, Forfeited or cancelled	(532,911)
Restricted Stock Units Outstanding, Vested	(141,185)
Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance	5,490,504
Weighted-Average Grant Date Fair Value per Share
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance	$ 37.41
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted	12.17
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited or cancelled	17.37
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested	44.57
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance	$ 16.40

Equity Incentive Plans - Summ_4

Equity Incentive Plans - Summary of Estimated Grant Date Fair Value of Stock Options Granted (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	1.70%	0.50%
Risk-free interest rate, maximum	2.50%	1.10%
Expected volatility, minimum	68.20%	67.10%
Expected volatility, maximum	69.80%	68.40%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 12.14	$ 43.68
Expected term (in years)	5 years 3 months 7 days	5 years 3 months 7 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 14.95	$ 66.50
Expected term (in years)	6 years 29 days	6 years 29 days

Equity incentive Plans - Summ_5

Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUs Included on Unaudited Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 12,861	$ 8,484
Cost of Revenue
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	795	328
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	4,345	2,883
Sales and Marketing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	3,229	2,495
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 4,492	$ 2,778

Equity incentive Plans - Schedu

Equity incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Nonvested Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized Share-Based Compensation Expense	$ 102,285
Remaining Weighted-Average Recognition Period (in years)	3 years 7 days
Nonvested Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized Share-Based Compensation Expense	$ 85,458
Remaining Weighted-Average Recognition Period (in years)	3 years 7 months 17 days
Nonvested Market-Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized Share-Based Compensation Expense	$ 4,553
Remaining Weighted-Average Recognition Period (in years)	2 years 11 months 4 days

Restructuring - Additional Info

Restructuring - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)Employee	Dec. 31, 2022USD ($)
Restructuring Cost And Reserve [Line Items]
Restructuring, reduction in workforce | Employee	100
Estimated aggregate restructuring costs recognized	$ 2
Restructuring costs paid	$ 1.4
Forecast
Restructuring Cost And Reserve [Line Items]
Remaining cash payments expected to be disbursed		$ 0.6

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Net loss attributable to Adaptive Biotechnologies Corporation	$ (62,736)	$ (40,642)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	141,697,252	138,967,754
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$ (0.44)	$ (0.29)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	15,996,713	13,790,289
Common Stock Options Granted
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	13,255,459	13,516,949
Nonvested Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	2,587,492	238,583
Nonvested Market-based Restricted Stock Units Granted
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	153,762
Common Stock Warrant
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities		34,757